Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 1, pp 87–91 | Cite as

Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries

  • Feng Lu
  • Katie J. SudaEmail author
  • Katherine E. Marks
Research Article

Abstract

Background For the past 30 years, clinical trials have been increasingly conducted in developing countries. These trials allow results to be generalizable to similar populations, offer access to treatment for patients in need, and examine diseases with differing patterns than developed countries. However, the characteristics of antineoplastic clinical trials and recent trends in study location in developing countries are unknown. Objective The primary objective was to evaluate the location, study phase, results, funding source, and ethics board approval of randomized double-blind controlled clinical trials evaluating antineoplastic agents by geographic location. Setting This is a retrospective evaluation of studies indexed in the PubMed/Medline database published in 2007–2011. Methods Clinical trials were identified with the search terms “drug therapy”, “antineoplastic agents” and “double blind method” and limited to English language, human, and randomized controlled trial. Main Outcome Measure We assessed frequencies of characteristics of antineoplastic clinical trials. Results A total of 116 trials evaluating antineoplastic drug therapy were identified. The highest frequency of clinical trials were published in 2009 (27.6 %), followed by 2011 (23.3 %), 2010 (20.7 %), 2007 (14.6 %), and 2008 (13.8 %). According to geographic region, 33.8 % were conducted in North America, followed by Europe (31.5 %) and Asia (16.2 %). Based on economic status, the majority (77.8 %) of clinical trial locations were in developed countries and 22.2 % were in developing countries. No significant difference was found between study locations in developed countries and developing countries from 2007 to 2011. When comparing studies conducted in developing and developed countries, there was no difference in the year published, study phase, results, funding source, or investigational review board approval and informed consent. Studies conducted in developed countries were significantly more likely to be single country studies (p = 0.02) and published in a journal with an impact factor greater than 10 (p = 0.013) when compared to studies conducted in developing countries. Conclusions Based on economic status, there was no significant location change of antineoplastic clinical trials from 2007 to 2011. Clinical trials conducted in developing countries were more often multi-country studies and published in journals with lower impact factors.

Keywords

Antineoplastic agents Clinical trials Developing countries Geographic location 

Notes

Acknowledgments

None.

Funding

There was no funding for this study.

Conflicts of interest

Dr. Suda and Mrs. Lu do have any conflicts of interest to disclose. Dr. Marks is an employee of Med Communications, Inc.

References

  1. 1.
    Clinical Trials. gov. A service of the U.S. National Institutes of Health. Understanding clinical trials. 2012. http://clinicaltrials.gov/ct2/info/understand. Accessed 6 Aug 2012.
  2. 2.
    Yusuf S. Clinical research and trials in developing countries. Stat Med. 2002;21:2859–67.PubMedCrossRefGoogle Scholar
  3. 3.
    Devasenapathy N, Singh K, Prabhakaran D. Conduct of clinical trials in developing countries: a perspective. Curr Opin Cardiol. 2009;24(4):295–300.PubMedCrossRefGoogle Scholar
  4. 4.
    World Medical Association. WMA declaration of Helsinki—ethical principles for medical research involving human subjects. 2012. http://www.wma.net/en/30publications/10policies/b3/. Accessed 6 Aug 2012.
  5. 5.
    U.S. Department of Health and Human Services. The Belmont report. 2012. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed 6 Aug 2012.
  6. 6.
    Shapiro HT, Meslin EM. Ethical issues in the design and conduct of clinical trials in developing countries. N Engl J Med. 2001;345(2):139–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Kasper CK. Conduct of clinical trials in developing countries. Haemophilia. 2002;8(3):166–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA. 2000;283(20):2701–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Frimpong-Mansoh A. Culture and voluntary informed consent in African health care systems. Dev World Bioeth. 2008;8:104–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Epstein M. Clinical trials in the developing world. Lancet. 2007;369:1859.PubMedCrossRefGoogle Scholar
  11. 11.
    Jalali R. Conduct of clinical trials in developing countries. Lancet. 2007;370:562.PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization. The top 10 causes of death. 2012. http://www.who.int/mediacentre/factsheets/fs310/en/index.html. Accessed 6 Aug 2012.
  13. 13.
    Food and Drug Administration. 35 innovative new drugs approved in fiscal year 2011. 2012. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm278383.htm. Accessed 6 Aug 2012.
  14. 14.
    Hoffman JM, Doloresco F, Vermeulen LC, Shah ND, Matusiak L, Hunkler RJ, Schumock GT. Projecting future drug expenditures -2010. Am J Health Syst Pharm. 2010;67:919–28.PubMedCrossRefGoogle Scholar
  15. 15.
    The World Bank Group. Glossary. 2012. http://www.worldbank.org/depweb/english/beyond/global/glossary.html. Accessed 6 Aug 2012.
  16. 16.
    Buchkowsky SS, Jewesson PJ. Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother. 2004;38(4):579–85.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.College of PharmacyUniversity of Tennessee Health Science CenterMemphisUSA

Personalised recommendations